EASIER试验:超声引导下竖脊肌平面阻滞与静脉吗啡治疗急诊肝胰胆疼痛的单中心开放标签随机对照试验
该单中心开放标签随机对照试验在2023年3月至8月急诊科纳入70例严重肝胰胆疼痛成人患者,干预组35例接受T7水平双侧超声引导下竖脊肌平面阻滞(0.2%罗哌卡因),对照组35例接受0.1 mg/kg静脉吗啡。干预组在1、3、5、10小时的NRS降幅均显著大于对照组(t检验,p<0.001),1小时NRS经ANCOVA分析显著更低(p<0.001)。干预组5小时(p=0.031)和10小时(p=0.04)需要补救镇痛的患者更少,各时间点「非常满意」的患者更多(p<0.001)。作者认为ESPB是肝胰胆疼痛中吗啡的有前景的替代方案。
要点
- 严重肝胰胆疼痛成人(NRS>6、年龄>18且<80岁)中,T7水平双侧超声引导下竖脊肌平面阻滞使用0.2%罗哌卡因,由受训急诊顾问医师操作。
- 干预组1、3、5、10小时NRS降幅分别为7±1.6、6.7±1.9、6.6±1.8、6.1±1.9,均显著大于对照组的4.4±2、4.6±1.8、3.7±2.2、3.8±1.8(t检验,p<0.001)。
- 1小时NRS在ESPB组显著更低(ANCOVA p<0.001)。
- ESPB组在5小时(t检验,p=0.031)和10小时(t检验,p=0.04)需要补救镇痛的患者更少。
- 各时间点ESPB组「非常满意」的患者均多于单纯吗啡组(p<0.001);作者认为ESPB是肝胰胆疼痛中吗啡的有前景的替代方案。
适用人群与场景
- 急诊科成人严重肝胰胆疼痛患者,NRS>6,年龄>18且<80岁。
- 排除:不同意者、NRS≤6、年龄≤18或≥80岁、妊娠、病情不稳定、对局部麻醉药或阿片类药物过敏者。
- 研究在三级医院急诊科进行,仅在主要研究者在场时招募。
诊断标准与关键阈值
- 疼痛采用10分数字评定量表(NRS)评估,由研究者在就诊时及干预后1、3、5、10小时评估。
- 纳入要求严重疼痛且NRS>6;NRS≤6被排除。
处置流程与药物剂量
- 干预组:由受训急诊顾问医师实施T7水平双侧超声引导下竖脊肌平面阻滞,使用0.2%罗哌卡因。
- 对照组:0.1 mg/kg静脉吗啡。
- 记录补救镇痛需求和患者满意度。
研究设计与关键结果
- 单中心开放标签随机对照试验,2023年3月至8月纳入70例患者,干预组35例、对照组35例;平均年龄40.4±13.2岁。
- 就诊时平均NRS:干预组8.0±0.9,对照组7.6±0.6。
- 1小时NRS在ESPB组显著更低(ANCOVA p<0.001)。
- 1、3、5、10小时NRS降幅:干预组7±1.6、6.7±1.9、6.6±1.8、6.1±1.9,对照组4.4±2、4.6±1.8、3.7±2.2、3.8±1.8,干预组均显著大于对照组(t检验,p<0.001)。
- 需要补救镇痛的患者:ESPB组在5小时(t检验,p=0.031)和10小时(t检验,p=0.04)更少。
- 各时间点ESPB组「非常满意」的患者均多于单纯吗啡组(p<0.001)。
证据类型、等级与局限
- 证据类型:单中心开放标签随机对照试验。
- 试验注册号:CTRI/2023/03/050595。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ESPB是肝胰胆疼痛患者中吗啡的有前景的替代方案。
- 适用人群为急诊科成人严重肝胰胆疼痛(NRS>6、年龄>18且<80岁)患者;排除不同意、NRS≤6、年龄≤18或≥80岁、妊娠、病情不稳定、对局部麻醉药或阿片类药物过敏者。
- ESPB由受训急诊顾问医师在T7水平双侧实施,使用0.2%罗哌卡因。
指南或共识出处
- EASIER试验(Erector-spinAe analgeSia for hepatopancreaticobiliary pain In the Emergency Room),发表于Emerg Med J。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ultrasound-guided (USG) erector-spinae plane block (ESPB) may be better than intravenous opioids in treating acute hepatopancreaticobiliary (HPB) pain in the ED.
METHODS: This open-label randomised controlled trial was conducted in the ED of a tertiary-care hospital between March and August 2023. All adult patients with severe HPB pain were recruited during times that a primary investigator was present. Unconsenting patients, numeric rating scale (NRS) ≤6, age ≤18 and ≥80 years, pregnant, unstable or with allergies to local anaesthetics or opioids were excluded. Patients in the intervention arm received bilateral USG ESPB with 0.2% ropivacaine at T7 level, by a trained ED consultant, and those in the control arm received 0.1 mg/kg intravenous morphine. Pain on a 10-point NRS was assessed by the investigators at presentation and at 1, 3, 5 and 10 hours after intervention by the treatment team, along with rescue analgesia requirements and patient satisfaction. Difference in NRS was analysed using analysis of co-variance (ANCOVA) and t-tests.
RESULTS: 70 participants were enrolled, 35 in each arm. Mean age was 40.4±13.2 years, mean NRS at presentation in the intervention arm was 8.0±0.9 and 7.6±0.6 in the control arm. NRS at 1 hour was significantly lower in the ESPB group (ANCOVA p<0.001). At 1, 3, 5 and 10 hours, reduction of NRS in the intervention arm (7±1.6, 6.7±1.9, 6.6±1.8, 6.1±1.9) was significantly greater than the control arm (4.4±2, 4.6±1.8, 3.7±2.2, 3.8±1.8) (t-test, p<0.001). Fewer patients receiving ESPB required rescue analgesia at 5 (t-test, p=0.031) and 10 hours (t-test, p=0.04). More patients were 'very satisfied' with ESPB compared with receiving only morphine at each time period (p<0.001).
CONCLUSION: ESPB is a promising alternative to morphine in those with HPB pain.
TRIAL REGISTRATION NUMBER: CTRI/2023/03/050595.
参考来源
- David SN, Murali V, Kattumala PD, et al. EASIER trial (Erector-spinAe analgeSia for hepatopancreaticobiliary pain In the Emergency Room): a single-centre open-label cohort-based randomised controlled trial analysing the efficacy of the ultrasound-guided erector-spinae plane block compared with intravenous morphine in the treatment of acute hepatopancreaticobiliary pain in the emergency department. Emerg Med J. 2024. PMID: 38977292. doi:10.1136/emermed-2023-213799
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。